These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15964626)

  • 1. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the role of bupropion.
    Kast RE
    Leuk Res; 2005 Dec; 29(12):1459-63. PubMed ID: 15964626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
    Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
    Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further observations on the fetal inflammatory response syndrome: a potential homeostatic role for the soluble receptors of tumor necrosis factor alpha.
    Romero R; Maymon E; Pacora P; Gomez R; Mazor M; Yoon BH; Berry SM
    Am J Obstet Gynecol; 2000 Nov; 183(5):1070-7. PubMed ID: 11084543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion.
    Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Centorrino T; Siriwardena AK; Cuzzocrea S
    Shock; 2007 May; 27(5):542-51. PubMed ID: 17438460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of tumor necrosis factor receptors 1 and 2 of the goldfish (Carassius aurutus L.).
    Grayfer L; Belosevic M
    Mol Immunol; 2009 Jul; 46(11-12):2190-9. PubMed ID: 19446337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid.
    Cowin AJ; Hatzirodos N; Rigden J; Fitridge R; Belford DA
    Wound Repair Regen; 2006; 14(4):421-6. PubMed ID: 16939569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effects of etanercept (TNFR:Fc) and its use in a patient with Crohn's disease.
    Srivastava MD
    Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):125-41. PubMed ID: 11458980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice.
    Brustolim D; Ribeiro-dos-Santos R; Kast RE; Altschuler EL; Soares MB
    Int Immunopharmacol; 2006 Jun; 6(6):903-7. PubMed ID: 16644475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-TNF alpha in dermatology].
    Mahe E; Descamps V
    Ann Dermatol Venereol; 2002 Dec; 129(12):1374-9. PubMed ID: 12536174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha.
    Kast RE; Altschuler EL
    Arch Immunol Ther Exp (Warsz); 2005; 53(2):143-7. PubMed ID: 15928583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies.
    Tsimberidou AM; Giles FJ
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):277-86. PubMed ID: 12113051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
    Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Caminiti R; Esposito E; Di Bella P; Cuzzocrea S
    Shock; 2008 May; 29(5):560-71. PubMed ID: 17724436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.
    Madhusudan S; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Ganesan TS
    J Clin Oncol; 2005 Sep; 23(25):5950-9. PubMed ID: 16135466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG; Markomichelakis NN; Sfikakis PP
    Retina; 2007; 27(4):399-413. PubMed ID: 17420690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
    Akiyama Y; Mimura T
    Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
    Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
    Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity.
    Abe Y; Yoshikawa T; Kamada H; Shibata H; Nomura T; Minowa K; Kayamuro H; Katayama K; Miyoshi H; Mukai Y; Yoshioka Y; Nakagawa S; Tsunoda S; Tsutsumi Y
    J Immunol Methods; 2008 Jun; 335(1-2):71-8. PubMed ID: 18417150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.